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Abstract
Background: Eosinophils not only defend the body against parasitic infection but are also involved in pathological
inflammatory allergic diseases such as asthma, allergic rhinitis and contact dermatitis. Clearance of apoptotic eosinophils by
macrophages is a key process responsible for driving the resolution of eosinophilic inflammation and can be defective in
allergic diseases. However, enhanced resolution of eosinophilic inflammation by deliberate induction of eosinophil
apoptosis using pharmacological agents has not been previously demonstrated. Here we investigated the effect of a novel
cyclin-dependent kinase inhibitor drug, AT7519, on human and mouse eosinophil apoptosis and examined whether it could
enhance the resolution of a murine model of eosinophil-dominant inflammation in vivo.
Methodology/Principal Findings: Eosinophils from blood of healthy donors were treated with AT7519 and apoptosis
assessed morphologically and by flow-cytometric detection of annexin-V/propidium iodide staining. AT7519 induced
eosinophil apoptosis in a concentration dependent manner. Therapeutic administration of AT7519 in eosinophil-dominant
allergic inflammation was investigated using an established ovalbumin-sensitised mouse model of allergic pleurisy.
Following ovalbumin challenge AT7519 was administered systemically at the peak of pleural inflammation and
inflammatory cell infiltrate, apoptosis and evidence of macrophage phagocytosis of apoptotic eosinophils assessed at
appropriate time points. Administration of AT7519 dramatically enhanced the resolution of allergic pleurisy via direct
induction of eosinophil apoptosis without detriment to macrophage clearance of these cells. This enhanced resolution of
inflammation was shown to be caspase-dependent as the effects of AT7519 were reduced by treatment with a broad
spectrum caspase inhibitor (z-vad-fmk).
Conclusions: Our data show that AT7519 induces human eosinophil apoptosis and enhances the resolution of a murine
model of allergic pleurisy by inducing caspase-dependent eosinophil apoptosis and enhancing macrophage ingestion of
apoptotic eosinophils. These findings demonstrate the utility of cyclin-dependent kinase inhibitors such as AT7519 as
potential therapeutic agents for the treatment of eosinophil dominant allergic disorders.
Citation: Alessandri AL, Duffin R, Leitch AE, Lucas CD, Sheldrake TA, et al. (2011) Induction of Eosinophil Apoptosis by the Cyclin-Dependent Kinase Inhibitor
AT7519 Promotes the Resolution of Eosinophil-Dominant Allergic Inflammation. PLoS ONE 6(9): e25683. doi:10.1371/journal.pone.0025683
Editor: Patricia T. Bozza, Fundac¸a˜o Oswaldo Cruz, Brazil
Received May 25, 2011; Accepted September 8, 2011; Published September 30, 2011
Copyright:  2011 Alessandri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by a Medical Research Council grant (G0601481) and Wellcome Trust grants (WT082181) and (WT094415). ALA is currently
funded through a Chief Scientist Office (Scotland) awarded research grant: ETM/86. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflict: The authors have a non-financial academic link with Astex
Therapeutics who kindly gifted them with the cyclin-dependent kinase inhibitor, AT7519. This compound is also commercially available (Selleck). This does not
alter the authors’ adherence to all PLoS ONE policies on sharing data and materials.
* E-mail: rodger.duffin@ed.ac.uk
Introduction
Eosinophils play a key role in the pathogenesis and propagation
of allergic diseases, including asthma and allergic rhinitis [1]. In
asthmatic patients, eosinophil infiltration into tissue probably
contributes to several clinical features, including tissue remodeling
and airway hyperresponsiveness [2,3]. Thus understanding the
mechanisms responsible for the recruitment, persistence and
clearance of eosinophils in allergic inflammation is required.
Increased understanding of the molecular and cellular basis for the
action of drugs commonly used in allergic disorders (such as
glucocorticosteroids), along with the development of novel
treatment strategies, is imperative given that many patient are
poorly responsive to glucocorticoid therapy [3,4].
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The accumulation of eosinophils and other leukocytes in tissues
depends not only on the number of cells being recruited but also
on the number of cells that are cleared from or leave the tissue[5].
In the lung current evidence suggests that transepithelial migration
of airway wall leukocytes followed by mucociliary clearance and/
or uptake of apoptotic cells by macrophages are important
mechanisms responsible for physiological clearance of inflamma-
tory lung cells [6,7,8]. Timely apoptosis and subsequent phago-
cytosis of inflammatory cells ensures that cell membrane integrity
is preserved, therefore preventing the release of cytotoxic
mediators with subsequent tissue damage and perpetuation of
the inflammatory response. Such nonphlogistic clearance of
inflammatory eosinophils may be defective in allergic diseases as
reduced levels of eosinophil apoptosis in sputum, as well as
defective macrophage phagocytosis, are associated with increased
asthma severity [9,10,11,12]. Similarly, studies have provided
evidence that glucocorticoids, one of the main treatments in severe
allergic disorders such as asthma, not only induce eosinophil
apoptosis but also enhance macrophage efferocytosis of apoptotic
cells[11,13]. Thus a pharmacological strategy that enhances
eosinophil apoptosis and drives subsequent clearance by phago-
cytes prior to inflammatory cell membrane rupture would make an
attractive potential therapeutic agent for the treatment of
eosinophil dominant allergic diseases.
One group of agents that has attracted attention is the cyclin-
dependent kinase (CDK) inhibitor (CDKi) class of drugs [14,
15,16,17]. The CDK enzymes are key regulators of the cell-cycle
and are activated by periodic formation of complexes with
cyclins (proteins that are present only at specific stages of the
cell-cycle) [15,17]. The activity of CDKs can be modulated by
low molecular weight CDKi drugs that attach to the ATP-
binding pocket or by modifying the composition of CDK/CDKi
drug complexes [18]. Indeed, CDKi drugs are currently under-
going clinical trials for oesophageal, prostate and lung cancers
[19]. Furthermore, CDKs have been associated with transcrip-
tion, neural function and apoptosis [15,18,20]. Our group has
demonstrated that the CDKi, R-roscovitine, induces neutrophil
apoptosis in vitro and enhances resolution of established
neutrophil-dependent inflammation in vivo [17]. In addition, we
were the first to show that R-roscovitine induces rapid and
efficacious human eosinophil apoptosis [14]. The novel CDKi,
AT7519, a selective inhibitor of several CDKs (especially CDKs
1, 2, 4, 5 and 9), has been shown to have antitumor activity in
vitro and in vivo [21,22,23,24]. AT7519 has an attractive
biological profile, demonstrating a good aqueous thermodynam-
ic solubility and its synthetic tractability makes it easily amenable
to large-scale synthesis. Currently, AT7519 has completed
phase-I studies in patients with refractory solid tumours [25].
However, little is known of the effects of CDKi drugs on the
molecular mechanisms responsible for eosinophil survival and/
or apoptosis in vivo.
Here, we investigate the effects of AT7519 on human eosinophil
apoptosis in vitro as well as the resolution phase of established
eosinophilic inflammation in vivo. We provide evidence that
AT7519 induces a caspase-dependent pro-apoptotic effect in
eosinophils and enhances the resolution of established eosinophil-
dominant allergic pleurisy by apoptosis of inflammatory cells.
Results
The CDKi drug, AT7519, drives primary human eosinophil
apoptosis in a concentration-dependent manner
We have recently demonstrated that human eosinophils
undergo apoptosis following treatment with R-roscovitine in vitro
[14]. Initial experiments were designed to evaluate whether
AT7519 has the same ability to induce eosinophil apoptosis
directly in vitro as R-roscovitine. This was important to establish as
the pharmacological kinase inhibition profile of these agents
differs. Human eosinophils were incubated for a 4 h period with
increasing concentrations from 1 nM–20 mM AT7519. As a
positive control we used increasing concentrations of 20–50 mM
R-roscovitine. Apoptosis was assessed by flow cytometric analysis
using annexin-V/Propidium iodide (PI) staining. The annexin-V/
PI dual negative cells were considered viable, the annexin-V-
positive PI-negative cells were considered apoptotic and annexin-
V/PI dual positive cells were considered necrotic. AT7519, like R-
roscovitine, markedly increased eosinophil apoptosis in a concen-
tration-dependent manner (Figure 1A). However, it is apparent
that AT7519 is ,50 times more potent at inducing apoptosis than
R-roscovitine (Figure 1A). It was also observed that at concentra-
tions which induced similar levels of apoptosis (1 mM AT7519 and
50 mM R-Roscovitine) AT7519 was less likely to cause necrosis of
eosinophils than R-Roscovitine (Figure 1A). Apoptosis was also
assessed morphologically using light microscopy after cytocentri-
fugation and staining with Diff-QuickTM (Figure 1B-C), confirm-
ing flow cytometric data.
To address whether AT7519 induces eosinophil activation, we
investigated the effect of the compound alone, and in the presence
of eosinophil activating agents on two very sensitive assays of early
eosinophil activation; namely i) shape change as measured by
increases in forward scatter detected by flow cytometry and ii)
intracellular calcium flux as measured by alterations in spectro-
fluorescence using Fura-2 loaded human eosinophils. AT7519 at
1 mM (a concentration that markedly induces human eosinophil
apoptosis) does not induce shape change or a direct increase in
intracellular free calcium concentration. Furthermore, the com-
pound does not affect the responses induced by eotaxin, platelet
activating factor (PAF) or the formylated chemotactic peptice
(fMLP); it neither augments nor, indeed, inhibits the responses to
these agonists (data not shown). We are confident that AT7519
does not directly activate eosinophils especially since calcium flux
is a key signaling pathway for subsequent eosinophil activation
(e.g., LTC4 synthesis).
AT7519 promotes resolution of allergic pleurisy in mice
Having demonstrated in vitro that eosinophil apoptosis was
markedly induced by AT7519, we investigated the ability of this
agent to resolve eosinophil-dominant inflammation in vivo. We
used a well-established murine model of acute eosinophilic
inflammation, allergic pleurisy [26]. In this model, eosinophil
influx is first detectable at 12 h post OVA challenge, becoming
maximal at 24–48 h and dropping to near basal levels
thereafter. Thus, this experiment evaluated the effects of
systemic administration of AT7519 given at the peak of
inflammation after the cells have migrated to the cavity (24 h)
but before they have been cleared (after 72 h). Pleural lavage
was performed 24 h after AT7519 treatment (48 h after OVA-
challenge) (See schematic representation in Figure 2A). Injec-
tion of 1 mg of ovalbumin (OVA) into the pleural cavity of sen-
sitized mice induced an influx of leukocytes, with an increase in
eosinophils, mononuclear cells and total number of leukocytes
in OVA-challenged mice (Figures 2B-D). Mice that were
treated intraperitoneally (i.p.) with AT7519 showed a marked
reduction in the numbers of total leucocytes, eosinophils and
mononuclear cells in the pleural cavity, consistent with
enhanced resolution of established eosinophilic inflammation
(Figure 2B-D).
Resolving Eosinophilic Allergic Inflammation
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AT7519 resolves allergic inflammation by driving
eosinophil apoptosis and clearance
We next investigated whether the enhanced resolution of
allergic pleurisy in the AT7519 treated group was due to induction
of eosinophil apoptosis and subsequent clearance of apoptotic cells
by macrophages. Given that AT7519 induced rapid eosinophil
apoptosis in vitro (Figure 1A), earlier time points were chosen for
pleural lavage in this set of experiments to ensure that any changes
in rates of eosinophil apoptosis were observed (See schematic
representation in Figure 3A). In the AT7519 treated group there
was a time-dependent decrease of eosinophil number which was
mirrored by an increase in the percentage of apoptotic eosinophils
as well as the percentage of macrophages containing apoptotic
bodies (Figures 3B-D). At 6 h post treatment typical morphology
of pleural cavity cells from vehicle treated animals demonstrating
viable eosinophils and macrophages without apoptotic bodies
(Figure 3E) and AT7519 treated animals demonstrating apoptotic
eosinophils as well as apoptotic eosinophils inside macrophages
(Figure 3F) are shown. Flow cytometric analysis of annexin-V/PI
staining of pleural cells further confirmed the ability of AT7519 to
induce time-dependent apoptosis of granulocytes (Figure 4A). A
representative flow cytometric profile (forward/side scatter) of
pleural lavage cells (Figure 4B) and representative histograms of
annexin-V positivity (FL-1, x-axis) of gated granulocytes and non-
granulocyte cells are shown for vehicle and AT7519 treated
animals (Figure 4C). Importantly AT7519 treatment did not effect
rates of apoptosis in non-granulocyte cells (Figure 4A) confirming
that enhanced resolution of inflammation was not due to a toxic or
apoptosis inducing effect of AT7519 on mononuclear cells in vivo.
AT7519 increases resolution of allergic pleurisy by
inducing caspase-dependent apoptosis of inflammatory
cells
Having demonstrated enhancement of eosinophil apoptosis by
AT7519 in vivo, we investigated whether the caspase pathway was
involved in the underlying mechanism. To determine this, we
utilised a protocol which allows the inhibition of caspase
machinery in vivo by zVAD-fmk[17]. Immunized animals were
treated with AT7519 and/or zVAD-fmk i.p. 24 h after antigen-
challenge and three additional doses of zVAD-fmk were given (See
schematic representation in Figure 5A). The mice were killed 30 h
or 48 h post antigen-challenge. We chose the 30 h time point once
we observed that the greatest apoptotic response occurred 6 h post
AT7519 treatment (24 h OVA+6 h of AT7519, Figures 3C and
4A). Intraperitoneal injection of zVAD-fmk prevented the
AT7519-induced increased percentage of apoptotic eosinophils
by .62% compared to AT7519-treated animals (Figure 5B) and
also reduced the percentage of macrophages containing apoptotic
bodies (Figure 5C).
The caspase-dependency of the pro-resolution action of
AT7519 was further confirmed when inflammatory cells recovered
from the pleural cavity of OVA-challenged mice were treated ex
vivo with AT7519 in combination with zVAD-fmk (see Figure 6A).
AT7519 (10 mM) promoted an increased percentage of annexin-V
positive/PI negative cells (Figure 6B) when compared to control.
When the cells were pre-incubated with zVAD-fmk (100 mM) and
then treated with AT7519 30 minutes later, the pro-apoptotic
action of AT7519 was blocked (Figure 6B) further corroborating
the caspase-dependency of AT7519. As a positive control for
Figure 1. The CDKi drug AT7519 induces apoptosis in primary human eosinophils in a concentration dependent manner. (A)
Eosinophils were incubated for 4 h with R-roscovitine (20 mM–50 mM), AT7519 (1 nM–20 mM) or control prior to flow cytometry analysis of AnnV/PI
binding to show the percentage of viable, apoptotic and necrotic eosinophils. Data represent mean 6 SEM with n = 3. (B-C), Cytocentrifuge images
(400xMagnification). (B), Eosinophils after 4 hours of culture; black arrows indicate healthy, viable eosinophils and back arrow head indicating an
erythrocyte. (C), Eosinophils after 4 hours of AT7519 treatment (10 mM); black arrows indicate apoptotic eosinophils, white arrows indicate necrotic
eosinophils with extrusion of nuclei. *p,0.05, **p,0.01, ***p,0.001 versus DMSO control.
doi:10.1371/journal.pone.0025683.g001
Resolving Eosinophilic Allergic Inflammation
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induction of eosinophil apoptosis, we used the powerful anti-
inflammatory and eosinophil apoptosis–inducing agent, dexa-
methasone (1 mM)(30). Examples of flow cytometric profiles and
representative histograms are shown (Figure 6C-H).
Discussion
Eosinophils contribute to the pathogenesis of allergic disease
[1,2,3,5], and reduced levels of eosinophil apoptosis in sputum
correlate with asthma severity [12]. It is important to delineate the
mechanisms governing eosinophil lifespan and apoptosis as it is
clear that manipulation of eosinophil apoptosis provides an
attractive way of physiologically removing the pathological
influence of eosinophils in allergic disorders. In addition,
phagocytosis of apoptotic cells dampens the inflammatory reaction
by switching the ingesting pro-inflammatory macrophages to a
more pro-resolution, anti-inflammatory phenotype with enhanced
secretion of IL-10 and TGF-b [13,27,28,29,30].
We have previously shown that the archetypal CDKi, R-
roscovitine, induces neutrophil apoptosis in vitro by decreasing
levels of the pro-survival protein Mcl-1 to override the cyto-
protective effects of inflammatory mediators without directly
influencing key inflammatory signaling pathways [16]. Impor-
tantly, R-roscovitine also enhances resolution of established
neutrophil-dependent sterile inflammation in vivo using the
carrageenan pleurisy model as well as arthritis and bleomycin
models [17]. By utilizing transgenic zebrafish Renshaw and
colleagues have enabled tracking of all stages of the inflamma-
tory process and have likewise demonstrated the enhanced
resolution of inflammation using R-roscovitine [31]. Moreover,
Koedel and colleagues [32] have shown that R-roscovitine, in
combination with antibiotic therapy, enhances resolution of
experimental pneumococcal meningitis in mice by driving
neutrophil apoptosis. Recently, we demonstrated that eosinophils
undergo apoptosis following treatment with R-roscovitine in vitro
which is preceded by down-regulation of the anti-apoptotic
protein Mcl-1 [14]. Our findings are in accordance with previous
studies in vitro which show that members of the Bcl-2 family and
caspases are central to the mechanism by which eosinophils
undergo apoptosis [33,34].
Figure 2. AT7519 promotes resolution of allergic pleurisy in vivo. (A) Schematic representation of the protocol of the induction of pleurisy
and of the treatment with AT7519. Immunized mice were challenged with OVA or PBS and further 24 h and 36 h later, received a systemic injection
of AT7519 or vehicle. The number of eosinophils (B), mononuclear cells (C) and total cell counts (D) were assessed 48 h after antigen-challenge.
Results are expressed as mean 6 SEM of at least five mice in each group. (B-D) *P,0.05, ***P,0.001 when compared with PBS-injected mice;
#P,0.05, ### P,0.001 when compared with vehicle-treated, OVA-injected mice.
doi:10.1371/journal.pone.0025683.g002
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Here we show that the novel CDKi drug AT7519 induces
concentration-dependent eosinophil apoptosis in vitro and does so
with a potency 50 times greater than R-roscovitive. It is important
that any potential pro-resolution agent acting via induction of
eosinophil apoptosis is also able to overcome the delay of apoptosis
signalled via survival factors present in vivo. It is known that the
eosinophil apoptosis inducing effects of glucocorticoids are
overridden by survival signals conferred from IL-5 [35], perhaps
explaining the high frequency of glucocorticoid resistance seen in
allergic diseases [4]. R-Roscovitine is able to override the anti-
apoptotic effects of IL-5 [36], an effect also observed using
AT7519 (data not shown). We specifically selected the already well
characterized OVA-induced allergic pleurisy model as we have
previously shown that treatment with PI3K inhibitors after antigen
challenge markedly reduced eosinophil accumulation, an effect
associated with inhibition of Akt phosphorylation and increased
apoptosis [26]. Here we show for the first time that a CDKi drug is
able to enhance the resolution of established eosinophil-dominant
inflammation in vivo. Specifically, systemic AT7519 treatment at
the peak of the inflammatory process significantly reduced the
number of eosinophils, mononuclear cells and total inflammatory
cells present in the pleural cavity. Subsequently we demonstrate
that AT7519 enhances the resolution of allergic pleurisy by
inducing rapid time-dependent eosinophil apoptosis (assessed
morphologically and by flow cytometry). Although the absolute
levels of apoptosis at any given time point were low compared to
the changes observed in total eosinophil number, it is known that
small changes in the rates of apoptosis of immune cells can have a
significant effect on total cellular populations over time [17,31,
37,38]. Apoptotic eosinophils are recognized and ingested as intact
cells by macrophages, with macrophages that consume apoptotic
granulocytes changing to a pro-resolution phenotype that permits
them to release TGF-b and IL-10 [30,39,40]. Following AT7519
treatment the percentage of macrophages containing apoptotic
bodies in the pleural cavity increased, implying rapid recognition
and phagocytosis of apoptotic eosinophils was occurring in vivo.
Significantly, treatment with AT7519 did not affect rates of
apoptosis of non-granulocyte cells recovered from the pleural
Figure 3. AT7519 drives eosinophil apoptosis and subsequent clearance by macrophages as assessed by morphological analysis.
(A) Schematic representation of the experimental protocol. Immunized mice were challenged with OVA and 24 h later received AT7519 or vehicle.
Eosinophil number (B), percentage of apoptotic eosinophils (C) and percentage of macrophages containing apoptotic bodies (D) were assed 2, 4 and
6 h after AT7519 treatment. Results are expressed as the mean6 SEM of at least five mice in each group. (B-D) *P,0.05, **P,0.01, ***P,0.001 when
compared with vehicle-treated, OVA-injected mice. Representative images from vehicle (E) and AT7519 treated (F) animals are shown (Magnification
x400 (i) and x1000 (ii and iii)). In vehicle treated animals (E), black arrows indicate healthy, viable eosinophils while in AT7519-treated animals (F), black
arrows indicate typically apoptotic eosinophils and white arrows apoptotic cells inside macrophages.
doi:10.1371/journal.pone.0025683.g003
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cavity suggesting that the beneficial effects on inflammatory
resolution were not due to a toxic or apoptosis inducing effect on
non-granulocyte lineage cells. Therefore reductions in total
inflammatory cell and macrophage numbers are most likely a
secondary consequence of eosinophil apoptosis, with macrophage
numbers returning towards normal levels once the apoptotic cell
burden has been fully cleared.
Several studies have demonstrated that zVAD-fmk reduces
apoptosis in animal models including sepsis [41] ischemia-
reperfusion [42] and bleomycin-induced lung fibrosis [43].
Furthermore, 15-epi-lipoxinA4 overrides myeloperoxidase-driv-
en apoptotic signalling and accelerates the resolution of acute
lung injury through a caspase-mediated proapototic effect [44].
Recently we demonstrated that zVAD-fmk prevented rolipram-
induced resolution of pleurisy induced by LPS [45]. Similarly,
the systemic administration of zVAD-fmk inhibited R-roscov-
itine-induced decrease in inflammatory cells and oedema for-
mation in the pleural cavity in carrageenan-induced pleural
inflammation [17]. Here we have shown that zVAD-fmk
treatment markedly decreased the rate of AT7519-induced
eosinophil apoptosis as well as the number of macrophages
containing apoptotic bodies, demonstrating that AT7519 induces
caspase-dependent eosinophil apoptosis in vivo. Although zVAD-
fmk did not completely abolish the AT7519 mediated apoptotic
effect, either in vivo or in vitro, we feel that this is likely to
represent incomplete caspase inhibiton using z-VAD-fmk, rather
than the presence of an alternative caspase-independent
apoptosis pathway. Such controversy has recently been settled
in the neutrophil literature using the newer, more cell permeable
and less toxic broad spectrum caspase inhibitor Q-VD-OPh[46],
demonstrating that in neutrophils apoptosis can be almost
completely inhibited by use of this powerful broad spectrum
caspase inhibitor.
Farahi et al. [36] recently reported that R-roscovitine, whilst
inducing rapid apoptosis in eosinophils in vitro, had little effect on
the onset or resolution of eosinophilic inflammation in a murine
ovalbumin sensitisation model. Of note, the authors do show a
,40–50% reduction in eosinophil recovery from bronchoalveolar
lavage 72h after the final R-roscovitine challenge, although this
was deemed not significant. Furthermore, this group utilised a
treatment regimen of 10 mg/kg R-roscovitine delivered i.p. Our
own in vivo work with R-roscovitine [17], as well as several other
Figure 4. AT7519 drives granulocyte apoptosis as assessed by flow cytometry. Immunized mice were challenged with OVA and 24 h later
received AT7519 or vehicle and apoptosis assessed by flow cytometry at 2, 4 and 6 h (A). (B) Typical flow cytometric profile of pleural lavage cells
showing granulocytes and non-granulocyte cells gated on the basis of size and granularity. (C) Representative histograms of gated granulocytes from
vehicle treated (i) and AT7519 treated (ii) animals as well as representative histograms of gated non-granulocyte cells from vehicle treated (iii) and
AT7519 treated (iv) animals at 6 hours post treatment. ***P,0.001 when compared with vehicle-treated, OVA-injected mice.
doi:10.1371/journal.pone.0025683.g004
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studies[47,48] have used a 10-fold higher dose to achieve adequate
systemic levels of the drug. This lower dose and/or the well known
solubility and dispersion issues with certain CDKi compounds
(such as R-Roscovitine) may further explain a lack of any in vivo
tissue-specific effects observed in the aforementioned study. In
addition Farahi et al, like ourselves, have noted that R-roscovitine
causes increased eosinophil necrosis in vitro, an effect that is
markedly reduced at AT7519 concentrations that induce similar
levels of apoptosis. That R-roscovitine may also cause increased
eosinophil necrosis in vivo, with consequent exacerbation of the
inflammatory response, may also explain the relative lack of effect
of R-Roscovitine in that model.
In conclusion, our data show that AT7519 induces human
eosinophil apoptosis and enhances resolution of allergic
pleurisy by inducing caspase-dependent eosinophil apoptosis.
Resolution of inflammation is preceded by increased apoptosis
and macrophage ingestion of apoptotic eosinophils highlighting
the importance of phagocytic clearance of inflammatory cells to
the resolution process. We suggest that the non-inflammatory
clearance of apoptotic eosinophils by macrophages prevents not
only the spillage of histotoxic contents from activated dying
cells but may also transform the macrophage to an anti-
inflammatory/pro-resolution phenotype with enhanced secre-
tion of TGF-b and IL-10. Based upon our findings, we
acknowledge that further studies, ideally using airway eosino-
phillic-inflammation models and AT7519 as an example of the
latest generation of CDKi drugs would be a logical progression.
Phenotyping of resolution phase macrophages and measure-
ment of TGF-b and IL-10 in vivo would also enhance insight
into the mechanisms governing enhanced resolution of
inflammation. Local delivery of CDKi drugs directly to the
lungs by way of inhaled therapy should be tested for efficacy as
a strategy to reduce dose and consequently potential side effects
from systemic therapy. We anticipate that our findings will help
lead the way to potential therapeutic trials of CDKi drugs in
diseases where eosinophils contribute to the pathogenesis and
propagation of allergic inflammatory diseases. This may be
realised fairly quickly as the CDKi drug used in this study is in
the advanced stages of human clinical trials for various cancers
and within our own centre, an experimental trial in patients
with idiopathic pulmonary fibrosis is under design.
Materials and Methods
Ethics Statement
Ethics approval for granulocyte isolation was obtained from the
Lothian Research Ethics Committee; approval numbers #08/
S1103/38 or #1702/95/4/72, at the University of Edinburgh,
Queen’s Medical Research Institute, where participants were
recruited and experimentation was carried out. Written informed
consent was obtained from all participants involved.
Female Balb/C mice (8–10 weeks) were humanely maintained
and handled in accordance with the UK Home Office Animals
Scientific Procedures Act (Licence Number 60/3829). This licence
was approved by the University of Edinburgh Ethical Review
Committee (approval ID PL08-08).
Figure 5. AT7519 effects on eosinophil apoptosis and subsequent clearance by macrophages is caspase dependent. (A) Schematic
representation of the experimental protocol. Immunized mice were challenged with OVA and 24 h later were treated with AT7519 and/or zVAD-fmk.
The percentage of apoptotic eosinophils (B) and percentage of macrophages containing apoptotic bodies (C) was assessed 30 h after antigen-
challenge. Results are expressed as the % cells per cavity, as a mean 6 SEM of at least five mice in each group. ***P,0.001 when compared with
vehicle-treated, OVA-injected mice. #P,0.05, ### P,0.001 when compared with AT7519-treated, OVA-injected mice.
doi:10.1371/journal.pone.0025683.g005
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Figure 6. AT7519 induces caspase-dependent apoptosis of inflammatory eosinophils when cultured ex vivo. (A) Schematic
representation of the experimental protocol. Immunized mice were challenged with OVA and 24 h later cells from the pleural cavity were harvested.
Cells were cultured in control (DMSO), zVAD-fmk, AT7519, dexamethasone or combinations for 2, 4 or 6 hours prior to apoptosis assessment by flow
cytometric measurement of annexin-V and propidium iodide staining. **P,0.01, ***P,0.001 when compared with DMSO-treated cells; #P,0.05
Resolving Eosinophilic Allergic Inflammation
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Eosinophil isolation
Granulocytes were isolated from the peripheral venous blood of
healthy adult donors by dextran (Pharmacosmos) sedimentation
followed by centrifugation through discontinuous PBS-Percoll (GE
Healthcare) gradients [49,50]. Eosinophils were separated from
contaminating neutrophils using an immunomagnetic separation
step with sheep anti-mouse IgG-Dynabeads (Invitrogen) coated
with the murine anti-neutrophil antibody 3G8 as described [51].
Eosinophil purity was routinely greater than 95%.
Human eosinophil apoptosis assessment
Eosinophils were re-suspended in IMDM (PAA) with 10% FBS
(Biosera), penicillin (100 U/mL) and streptomycin (100 U/mL)
(PAA). Cells were aliquoted (56106 cells/mL) into a 96-well-flat-
bottomed-flexible-plate (BD Biosciences) in a final volume of
150 mL and incubated with R-roscovitine (Merck), AT7519
(Astex), zVAD-fmk (Bachem), Q-VD-OPh (R&D Systems), IL-5
(R&D Systems) or combinations of these at 37uC with 5% CO2 for
4 h. All stock reagents were initially dissolved in dimethylsulph-
oxide (Sigma) then diluted in buffer yielding a final concentration
of 0.2%; a corresponding DMSO control of 0.2% was assessed as
an appropriate vehicle control. Apoptosis was assessed by flow
cytometry using annexin-V-FLUOS (Roche) in combination with
propidium iodide (PI) (Sigma) as described previously [14].
Morphological apoptotic changes were assessed by light micros-
copy of DiffQuickTM stained cytocentrifuged cells [49,52].
Induction of pleurisy
Female Balb/C mice (8–10 weeks) were immunized with
ovalbumin (OVA) adsorbed to aluminium hydroxide gel as
described previously[26]. Briefly, mice were injected subcutane-
ously (s.c.) on days 1 and 7 with 0.2 mL of a solution containing
100 mg of OVA and 70 mg of aluminium hydroxide. Sensitized
mice were then challenged with OVA (1 mg/cavity, in a total
volume of 100 ml intrapleurally) or PBS and a further 24 h and
36 h later, received systemic AT7519 (30 mg/kg, intraperitoneally
(i.p.)) or PBS vehicle. The cells present in the pleural cavity were
harvested at different times after antigen-challenge by washing the
cavity with 2 mL of PBS and total cell counts performed in a
NucleoCounterH system using NucleoCassetteTM (Chemometec,
Denmark). For the experiments evaluating leukocyte apoptosis,
infiltrating leukocytes were examined at 2, 4 and 6 h (flow
cytometry) and 30 and 48 h (morphologic apoptosis) after drug
treatment. Differential cell counts were performed on cytocen-
trifugation preparations stained with DiffQuickTM. The results are
presented as the number or % cells per cavity as indicated in
figures.
Assessment of leukocyte apoptosis in pleurisy model
Apoptosis was assessed as described previously[17]. Briefly, cells
(56104) collected 30 or 48 h after antigen-challenge were
cytocentrifuged, fixed, stained and counted using oil immersion
microscopy (x100 objective) to determine the proportion of cells
with distinctive apoptotic morphology, with five hundred cells
counted per slide. Assessment of apoptosis was also performed by
flow cytometry using annexin-V-FLUOS in combination with
propidium iodide (PI). Annexin-V was diluted 1\500 in binding
buffer (HBSS+Ca2+) and 280 mL added to 20 mL of cells (56106
cells\mL). Samples were then incubated on ice at 4uC for
10minutes. Immediately prior to processing, 1 mL PI (1 mg\mL)
per sample was added. Results are expressed as cells undergoing
the early stage of apoptosis quantified by staining with annexin-V
but not PI. The cells were selected based on size and granularity,
allowing separate analysis of granulocyte population.
Administration of zVAD-fmk
Twenty-four hours after intrapleural injection of OVA, mice
were injected i.p with 30 mg/kg of AT7519 and/or 5 mg/kg of
zVAD-fmk. Three additional doses of zVAD-fmk were given i.p 4,
8, 12 h later and mice were killed 30 h after the OVA challenge.
Ex vivo culture of leukocytes
The cells present in the pleural cavity from mice immunized
according to the protocol above were harvested at 24 h after
antigen-challenge by washing the cavity with 2 mL of PBS and
were aliquoted (56106 cells/mL) into a 96-well-flat-bottomed-
flexible-plate (BD Biosciences) in a final volume of 150 mL at 37uC
with 5% CO2 for 2, 4 and 6 h.
Statistical analysis
All in vitro experiments were performed at least three times with
each experiment carried out in triplicate. All in vivo experiments
included 6 mice per group. Data were expressed as the mean
6SEM. The principal statistical test used for comparison of
multiple groups was one-way ANOVA with post hoc multivariate
analysis by Student Newman-Keuls (with a 95% confidence
interval). In order to test statistical significance between two groups
we used unpaired Student’s t test. Differences were considered
significant at *p,0.05, **p,0.01, ***p,0.001.
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